MolecuLightDX

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. July 21, 2021 MolecuLight Inc. Jordan John Director, Quality Assurance & Regulatory Affairs Suite 700, 425 University Avenue Toronto, Ontario M5G 1T6 Canada Re: K211901 Trade/Device Name: MolecuLightDX Regulation Number: 21 CFR 878.4550 Regulation Name: Autofluorescence Detection Device For General Surgery And Dermatological Use Regulatory Class: Class II Product Code: QJF, FXN Dated: June 21, 2021 Received: June 21, 2021 Dear Jordan John: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Purva Pandya Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use 510(k) Number (if known) K211901 Device Name MolecuLightDX Indications for Use (Describe) The MolecuLightDX is a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to - (i) View and digitally record images of a wound, - (ii) Measure and digitally record the size of a wound, and - (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. The fluorescence image, when used in combination with clinical signs and symptoms, has been shown to increase the likelihood that clinicians can identify wounds containing bacterial loads >104 CFU per gram as compared to examination of clinical signs and symptoms alone. The MolecuLightDX device should not be used to rule-out the presence of bacteria in a wound. The MolecuLightDX does not diagnose or treat skin wounds. | Type of Use (Select one or both, as applicable) | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | <span style="white-space: nowrap;"> <span style="font-size: 16px;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> <span style="white-space: nowrap;"> <span style="font-size: 16px;">□</span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ## K211901 ## 510(k) SUMMARY #### MolecuLightDX #### Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared MolecuLight Inc. Suite 700, 425 University Avenue Toronto, ON, Canada M5G 1T6 Phone: 416-542-5522 Contact Person: Jordan John Date Prepared: July 19, 2021 #### Name of Device MolecuLightDX #### Device Classification and Product Code Autofluorescence detection device, 21 CFR 878.4550, Class II, QJF Tape, Camera, Surgical, 21 CFR 878.4160, Class I, FXN #### Predicate Devices MolecuLight i:X K191371 #### Indications for Use The MolecuLightDX is a handheld imaging tool that allows clinicians diagnosing and treating skin wounds, at the point of care, to View and digitally record images of a wound, (i) Measure and digitally record the size of a wound, and (ii) (iii) View and digitally record images of fluorescence emitted from a wound when exposed to an excitation light. The fluorescence image, when used in combination with clinical signs and symptoms, has been shown to increase the likelihood that clinicians can identify wounds containing bacterial loads >104 CFU per gram as compared to examination of clinical signs and symptoms alone. The MolecuLightDX device should not be used to rule-out the presence of bacteria in a wound. The MolecuLightDX does not diagnose or treat skin wounds. {4}------------------------------------------------ ## Device Description The MolecuLightDX Imaging Device is a handheld medical imaging device comprised of a high-resolution color AMOLED display and touch-sensitive screen with integrated optical and microelectronic components. MolecuLightDX uses its patented technology to enable real-time standard digital imaging and fluorescence imaging in wounds and surrounding healthy skin of patients as well as wound area measurements. ## Non-Clinical Testing Nonclinical testing included the following on the subject device: - Standards Compliance Testing 1) - 2) Software Verification and Validation - 3) System Verification and Validation - 4) Accuracy and Inter/Intra Reader Variability Testing of Wound Measurement Function - ર) Packaging and Transport validation ## Compliance with Special Controls of 21 CFR 878.4550 The device complies with the following applicable special controls as per 21 CFR 878.4550 as follows: - Patient Contact Materials have been assessed to be biocompatible. 1. - 2. Performance testing demonstrated the electromagnetic compatibility and electrical, mechanical and thermal safety of the device. - Software verification and validation has been completed. 3. - ব LED light safety testing has been demonstrated according to IEC 60601-2-57:2011. - Labeling is provided that includes instructions for use as well as the performance of the device when 5. used as intended. Note: There are no components labeled as sterile included with this product. ## Standards Compliance MolecuLightDX has been tested to comply with the following FDA recognized standards: - . Safety Testing per IEC 60601-1:2005+A1:2012& US National Differences per ANSI/AAMI ES 60601-1:2005/A1:2012 - EMC Testing per IEC 60601-1-2:2014 4th Edition ● - LED Testing per IEC 60601-2-57:2011 and IEC 62471:2006 ● ## Software Verification and Validation Testing Software verification and validation testing was conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "moderate" level of concern. ## Comparison of Intended Use, Indications for Use and Technological Characteristics with the Predicate Device {5}------------------------------------------------ | | MolecuLightDX<br>SUBJECT DEVICE | MolecuLight i:X<br>PREDICATE DEVICE | |--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device Name | MolecuLightDX | MolecuLight i:X | | Manufacturer | MolecuLight Inc. | MolecuLight Inc. | | 510(k) Number | - | K191371 | | Regulatory Class | Class II | Class II | | Regulation<br>Number | QJF | QJF | | Product<br>Classification | 21 CFR 878.4550 | 21 CFR 878.4550 | | Classification<br>Name | Autofluorescence detection device for<br>general surgery and dermatological use | Autofluorescence detection device for<br>general surgery and dermatological use | | Intended Use | Intended for general surgery and<br>dermatological use as an adjunct tool that<br>uses autofluorescence to detect tissues or<br>structures. This device is not intended to<br>provide a diagnosis. | Intended for general surgery and<br>dermatological use as an adjunct tool<br>that uses autofluorescence to detect<br>tissues or structures. This device is not<br>intended to provide a diagnosis. | | Indications for<br>Use | The MolecuLightDX is a handheld imaging<br>tool that allows clinicians diagnosing and<br>treating skin wounds, at the point of care, to | The MolecuLight i:X is a handheld<br>imaging tool that allows clinicians<br>diagnosing and treating skin wounds, at<br>the point of care, to | | | i) View and digitally record images of a<br>wound,<br>ii) Measure and digitally record the size of<br>a wound, and<br>iii) View and digitally record images of<br>fluorescence emitted from a wound when<br>exposed to an excitation light. | i) View and digitally record images of<br>a wound,<br>ii) Measure and digitally record the<br>size of a wound, and<br>iii) View and digitally record images<br>of fluorescence emitted from a wound<br>when exposed to an excitation light. | | | The fluorescence image, when used in<br>combination with clinical signs and<br>symptoms, has been shown to increase the<br>likelihood that clinicians can identify<br>wounds containing bacterial loads >104<br>CFU per gram as compared to examination<br>of clinical signs and symptoms alone. The<br>MolecuLightDX device should not be used<br>to rule-out the presence of bacteria in a<br>wound.<br>The MolecuLightDX does not diagnose or<br>treat skin wounds. | The fluorescence image, when used in<br>combination with clinical signs and<br>symptoms, has been shown to increase<br>the likelihood that clinicians can identify<br>wounds containing bacterial loads >104<br>CFU per gram as compared to<br>examination of clinical signs and<br>symptoms alone. The MolecuLight i:X<br>device should not be used to rule-out the<br>presence of bacteria in a wound. | | | | The MolecuLight i:X does not diagnose<br>or treat skin wounds. | | Target Organ | Wounds | Wounds | | | MolecuLightDX<br>SUBJECT DEVICE | MolecuLight i:X<br>PREDICATE DEVICE | | Patient<br>Population | Adult Patients | Adult Patients | | Operating Modes | Standard and fluorescence imaging, video<br>and image capture | Standard and fluorescence imaging, video and image capture | | Excitation Light | 405nm light emitted from light emitting<br>diodes (LEDs) | 405nm light emitted from light emitting<br>diodes (LEDs) | | Laser Power<br>Density | N/A | N/A | | Infrared LED | N/A | N/A | | White LED | N/A | N/A | | Emission<br>Wavelength | 500-545nm and 600-665nm | 500-545nm and 600-665nm | | Contrast Agent | Not required - autofluorescent target | Not required - autofluorescent target | | Infrared Laser<br>Distance Finder<br>Wavelength | 940nm | 850nm | | Infrared Laser<br>Distance Finder<br>Peak Power Output | 17mW | 14mW | | Working<br>Distance | 8 – 12 cm (Fluorescence and Standard<br>Imaging)<br>8 – 20 cm (Measurement Mode) | 8-12cm (All imaging modes) | | Torch | Yes | No | | Optical head | 3 Camera System | 1 Camera | | Resolution (focal<br>plane) | 8 megapixels | 5 megapixels | | Magnification | N/A | N/A | | Maximum Frame<br>Rate | 30 images/sec | 30 images/sec | | Camera Bit<br>Depth | 8 bits | 8 bits | | Image Size<br>(Pixels) | 3264 x 2448 pixels | 1135 x 640 pixels | | Image Format | JPEG | JPEG | | Video Format | MOV | MOV | | Software<br>Operating System<br>(OS) | Android 9.1 | Apple iOS 9.3.5 | | Compatibility | | | | Measurement<br>Functionality | Stickerless Wound Measurement: Wound<br>length, width, and area measurements | Wound length, width, and area<br>measurements | | Shelf-Life | 2 Years | 2 Years | | Power Supply | Battery and wall | Battery and wall | | Display | 5.5" AMOLED | 4" LCD | | | MolecuLightDX<br>SUBJECT DEVICE | MolecuLight i:X<br>PREDICATE DEVICE | | Patient<br>Contacting<br>Materials | Non-patient contacting device (held 8-20cm from skin) | Non-patient contacting device (held 8-12cm from skin) | | Sterility | Used non-sterile | Used non-sterile | | Electrical Safety | Compliance to IEC 60601-1 | Compliance to IEC 60601-1 | | Mechanical safety | Compliance to IEC 60601-1 | Compliance to IEC 60601-1 | | Chemical Safety | No chemical delivered or used as part of the system | No chemical delivered or used as part of the system | | Standards with<br>which the Device<br>complies | IEC 60601-1<br>IEC 60601-1-2<br>IEC 60601-2-57<br>IEC 62471 | IEC 60601-1<br>IEC 60601-1-2<br>IEC 60601-2-57<br>IEC 62471 | # Table 1: Comparison of Technological Characteristics for Fluorescence Imaging {6}------------------------------------------------ {7}------------------------------------------------ ## Conclusion The performance tsting conducted on the MolecuLightDX demonstrates that the device can be used safely and effectively for the indications for use stated above. The MolecuLightDX's technological characteristics are similar to the technological characteristics of the predicate device (K191371) and does not raise new types of questions regarding safety and technology. The proposed MolecuLightDX is considered to be substantially equivalent to the MolecuLight i:X predicate device (K191371).